Taking advantage of the availability of several inhibitors of PI3K/mTOR signaling pathway developed as cancer drugs, we specifically evaluated the effect of Everolimus (mTOR inhibitor) MK2206 (Akt inhibitor) and BEZ235 (double mTOR/PI3K inhibitor) on our models. The gene discussed is AKT1; the disease is cancer.